159 related articles for article (PubMed ID: 22010386)
1. FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
Oncology (Williston Park); 2011 Sep; 25(10):904. PubMed ID: 22010386
[No Abstract] [Full Text] [Related]
2. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R
Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441
[TBL] [Abstract][Full Text] [Related]
3. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
[No Abstract] [Full Text] [Related]
5. Seattle Genetics rare cancer drug sails through accelerated approval.
DeFrancesco L
Nat Biotechnol; 2011 Oct; 29(10):851-2. PubMed ID: 21997610
[No Abstract] [Full Text] [Related]
6. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
Garnock-Jones KP
Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435
[TBL] [Abstract][Full Text] [Related]
12. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
Mei M; Thomas S; Chen R
BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
15. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Senter PD; Sievers EL
Nat Biotechnol; 2012 Jul; 30(7):631-7. PubMed ID: 22781692
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin.
Drugs R D; 2011; 11(1):85-95. PubMed ID: 21410298
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin.
Younes A; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Jan; 11(1):19-20. PubMed ID: 22212672
[No Abstract] [Full Text] [Related]
19. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
Fukuhara N; Yamamoto G; Tsujimura H; Chou T; Shibayama H; Yanai T; Shibuya K; Izutsu K
Leuk Lymphoma; 2020 Jan; 61(1):176-180. PubMed ID: 31437057
[No Abstract] [Full Text] [Related]
20. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
Broccoli A; Derenzini E; Pellegrini C; Narducci R; Stefani G; Casadei B; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):493-5. PubMed ID: 23726017
[No Abstract] [Full Text] [Related]
[Next] [New Search]
